Introduction
Acute myocardial infarction (AMI) is typically caused by platelet-mediated thrombosis at the site of a ruptured or eroded atherosclerotic plaque. Anti-platelet therapy with aspirin and clopidogrel is commonly prescribed early and continued following AMI to reduce recurrent ischemic events, but may cause an increase in the risk of bleeding. [1] [2] [3] Both recurrent ischemic events and bleeding have been associated with increased late mortality. 4, 5 Recent studies have demonstrated wide variability of individual patient responsiveness to the inhibitory effects of clopidogrel on platelet aggregation, [6] [7] [8] with potentially important implications for its clinical effectiveness and safety. Following percutaneous coronary intervention (PCI) or ACS, patients with low clopidogrel responsiveness and consequent high on-treatment platelet reactivity have a higher risk of recurrent ischemic events, [9] [10] [11] [12] while patients with enhanced platelet inhibition have lower risk of cardiovascular events 13 but a higher risk of bleeding.
14 Clopidogrel, which exerts its effects by inhibiting the platelet P2Y 12 adenosine diphosphate receptor, is a pro-drug that must be converted into its active metabolite by hepatic metabolism via multiple cytochrome (CYP) P450 isoenzymes, including CYP2C19, CYP1A2, CYP2B6, CYP2C9, and CYP3A. Functional variability in these CYP450 proteins, resulting from single nucleotide polymorphisms (SNPs) in the genes encoding them, has been shown to contribute to the observed variation in clopidogrel-induced platelet inhibition, [14] [15] [16] [17] [18] [19] and may account, at least in part, for differences in outcome among clopidogrel-treated patients. 
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pi id do l el h hi ich h ts i its ff ff ts b b i inhi hibi bi i ti th he l latel let P2 P2Y Y d de i sine reactivity, 15, 17, 18, 20 and an increased risk of adverse ischemic events after PCI. 21, 22 In contrast, increased metabolism of clopidogrel among patients with a gain-of-function allele such as CYP2C19*17 results in enhanced platelet inhibition 17 and is associated with an increased risk of bleeding after PCI. 14, 17 Notably, in 2010, the FDA required a "boxed warning" be added to the label for clopidogrel concerning the diminished effectiveness of the drug in patients with decreased CYP2C19 function due to genetic polymorphisms.
These previously reported effects of CYP gene polymorphisms on clopidogrel-related platelet responsiveness and outcomes have been observed in predominantly Caucasian or Asian populations after PCI. 14, 15, 17, 18, [20] [21] [22] [23] [24] The effect of CYP polymorphisms on cardiovascular events among clopidogrel-treated patients after an acute coronary syndrome remains controversial, 25 and no studies to date have investigated the association of these CYP variants with outcomes in African American patients. In consideration of the Institute of Medicine's recently articulated goal 26 to identify patient characteristics and treatments that vary by race in order to develop interventions that will minimize differences in care and eliminate disparities in outcomes, we investigated whether CYP variants were associated with different outcomes, including 1-year mortality, among clopidogrel-treated Caucasian and African American patients after AMI in the large, prospective, multicenter Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health status (TRIUMPH) cohort. 27 Our primary aim was to investigate whether CYP2C19*2 and CYP2C19*17 variants were associated with significantly different rates of 1-year mortality in Caucasian and/or African American post-MI patients discharged on clopidogrel. As a secondary aim, we sought to more comprehensively investigate previously-reported genetic variants in the genes encoding proteins involved in clopidogrel absorption and metabolism. Toward these two aims, we specifically investigated variants in .2%) %) %) %) w w w wer r er ere e e d d dis is is isch ch ch c ar r ar arge g g d nclu lu lu ude de de d d d d in n t t t the h h h pr r re r se e en n nt n ana na na naly ly lyse se se s s s. Gi Gi Gi G ve ve ve ven n n th th the lar r r rge ge ge e f f f fre re requ qu qu q en en n ncy cy cy c d d diffe fe fere re re renc c c ce e es e f f for or r or sev ev ev e e er e a of interest acro oss ss ss ss r r rac ac ac ace, e, e, w w w we e re re re rest st st s ri ri ri ict ct c cted ed ed d t t t the he he he a a ana na na aly ly ly l ses s s s to to to t s s s se el e elf f f---f f id id id iden en en nti ti tifi fi fied ed ed ed Caucasian and m m merican p pat atie ie ie ient nt ts, s s, y yie ie ie ield ld ld l in in in ng g a a fi fi fi fina na al l l l sa samp mp m le le le e s s siz iz iz ze e e of of of f 27 27 27 2732 32 32 32 sub ub ub bje je je j ct ct cts s s (2 (2 (2 206 06 06 0 2 2 2 2 Ca Ca Ca C ucasians s; laboratory results, disease severity and the processes of inpatient care. TRIUMPH received Institutional Review Board approval at all participating sites and written informed consent was obtained from each participant.
Mortality Assessment
One-year mortality in TRIUMPH patients discharged on clopidogrel was the primary outcome.
The Social Security Administration Death Master File was queried to determine patients' vital status as of 12/31/2010 (http://www.ntis.gov/products/ssa-dmf.asp) and was available for all patients in this study. Of note, this query was performed prior to new restrictions and expunging of some records from the database.
Cardiac Rehospitalization, Recurrent MI, Bleeding Outcomes
The secondary outcomes of cardiac rehospitalization, recurrent MI, and bleeding were only assessed for variants with a significant association with the primary outcome of 1-year mortality.
TRIUMPH follow-up has previously been described; 27, 30 briefly, follow-up was scheduled on all survivors at 1, 6, and 12 months. All follow-up interviews were conducted by telephone calls from a single, specialized center. If patients agreed to additional blood collection, an in-home visit was performed by trained medical personnel at 1 and 6 months. For those who did not agree to blood collection, 1 and 6 month interviews were performed by telephone from the same single specialized center as the 12 month interview. All patients were asked to report interval events (e.g., procedures, diagnostic tests, hospitalizations, and outpatient visits) since their last study contact. If a patient reported being hospitalized, records of that hospitalization were requested to adjudicate cardiovascular events, including MI, heart failure, or revascularization procedures. Chart abstractions were sent to 2 cardiologists for independent determination of the reason for hospitalization. If there was disagreement between the 2 cardiologists, the record was restrictions and exp xp xp xpu Minor ('nuisance' or BARC Type-1) 31 bleeding was determined by interview. 27 Any major or minor bleeding episode was counted as a bleeding outcome in this analysis.
Genotyping Methods and QC
DNA was isolated and purified from whole blood using the Qiagen QIAamp DNA purification kit (Quiagen, Germantown, MD). Genotyping of CYP and ABCB1 polymorphisms was performed by pyrosequencing or TaqMan assay. Pyrosequencing was performed as previously described. 30 PCR was carried out using Amplitaq Gold PCR master mix (ABI, Foster City, CA), 1 pmole of each primer (IDT, Coralville, IA), and 1ng DNA. Pyrosequencing primers and conditions are listed in Supplemental Table S1 . TaqMan genotyping assays (assay IDs listed in Supplemental Table S2 ) were performed according to manufacturer's directions (Applied Biosystems, Carlsbad, California). The DNA segments containing the region of interest were amplified with PCR using TaqMan genotyping master mix and 5-10ng DNA. Allelic discrimination was performed using sequence detection software (Applied Biosystems, Carlsbad, California). PCR and allelic discrimination were performed using the ABI 7500 real time PCR platform. All genotype data were transferred to a Microsoft Access database for permanent storage and merging with the clinical datasets through SAS v9.1.
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Statistical Analyses
Our primary aim was to investigate whether CYP2C19*2 (rs4244285) and CYP2C19*17 p=0.018). However, history of CHF was also included in the adjusted stratified proportional hazards models for CYP1A2*1C, described below. Categorical data are reported as frequencies and differences between groups were compared with chi-square or Fisher's exact tests, as appropriate. Continuous data are reported as mean ± standard deviation (SD) and differences between groups were tested using one-way analysis of variance. HWE was assessed using chisquare tests or Monte Carlo permutation with 10000 iterations, as appropriate. Kaplan-Meier estimates and Cox proportional hazards models were used to describe the effect of genotype on patients' survival, and log-rank p-values were determined. Follow-up began at the time of discharge from the index hospitalization. To estimate the independent contribution of genotype, stratified proportional hazards models were used, adjusting for sex and the GRACE score 32 for all outcomes except for bleeding where stratified proportional odds ratios (OR) were also adjusted for CRUSADE bleeding risk score. 33 Consistent with previous investigations, 16, 18, 20-22, did not differ betw w w wee ee ee een
Ameri i i icans wh h he h re t t t the he he her (rs11188072) and CYP2C19*17 -806 (rs12248560), and determined linkage, in our cohort, for these two variants. Given that the two CYP2C19*17 variants were in tight LD in our cohort (Supplemental Figure S1 ), consistent with others' data, 35 we restricted our analyses to the functional, 'defining' CYP2C19*17 variant (CYP2C19*17 -806; rs12248560) that is responsible for a C>T transition in the CYP2C19 promoter that creates a new consensus binding site for the GATA transcription factor family, resulting in increased CYP2C19 expression and activity. 36 For all CYP variants, *1 (or *1A, in the case of CYP1A2) was assigned in the absence of other alleles. Metabolizer status was defined according to the classification schema described by Mega et al. 22 
into ultra-rapid (UR), intermediate (IM), extensive (EM) and poor (PM)
metabolizers. If metabolizer status could not be assigned according to this classification schema, the subjects were excluded from metabolizer analysis. 37, 38 Analyses were performed with SAS version 9.2 (SAS Institute, Inc., Cary, NC) and R version 2.11.1. In TRIUMPH, given a mortality of 7.2% in African Americans discharged on clopidogrel, there was 80% or more power to detect a HR of 2.2 or above with a minor allele frequency of 0.21 or greater; given a mortality of 3.6% in Caucasians discharged on clopidogrel, there was 80% or more power to detect a HR of 2.1 or above with a minor allele frequency of 0.15 or greater.
Results

TRIUMPH Genetic Cohort
Between April 11, 2005 , and December 31, 2008, 2732 subjects (2062 Caucasians; 670 African Americans) were recruited and included in our study. Baseline characteristics of these subjects are shown in Table 1 . As seen in Table 1 , the African American subgroup consisted of more females and was slightly younger but had increased co-morbidities, including diabetes, kidney disease and heart failure. Nevertheless, the African American and Caucasian subgroups had similar mean GRACE scores at discharge. The 1-year mortality rate was 4.9% for Caucasians (N=102) and 9.7% for African Americans (N=65).
Overall, 79% of Caucasians (N=1632) and 64.4% of African Americans (N=430) were discharged on clopidogrel. Characteristics of subjects discharged on clopidogrel are shown in Table 1 . Similar to the entire cohort, the African American subgroup consisted of more females and was slightly younger but had increased co-morbidities, including diabetes, kidney disease and heart failure. They also had more peripheral vascular disease and were more likely to have had a previous MI or cerebrovascular accident. While the GRACE risk score was similar between Caucasians and African Americans, the CRUSADE bleeding score was significantly higher among African American TRIUMPH patients discharged on clopidogrel. Discharge beta- Table 1 . As seen in Table 1 American TRIUMPH patients discharged on clopidogrel, but African Americans discharged on clopidogrel were less likely to also be discharged on aspirin. More than 80% of TRIUMPH patients discharged on clopidogrel received in-hospital revascularization; the majority of these being PCI (87.1% of Caucasians and 77.4% of African Americans). The 1-year mortality rate for patients discharged on clopidogrel was 3.6% (N=59) for Caucasians and 7.2 % (N = 31) for African Americans.
Prevalence of CYP Variants in the TRIUMPH Cohort
Frequencies of genotyped variants in Caucasian and African American TRIUMPH patients (entire cohort including those discharged on clopidogrel and those not treated with clopidogrel)
are shown in Supplemental Table S3 . All of the variants were similar in frequency to those 
Single Variant Association with Mortality According to Race
In Caucasian TRIUMPH subjects discharged on clopidogrel, the CYP2C19*2 variant was associated with significantly increased all-cause mortality (5. American TRIUMPH patients discharged on clopidogrel was borderline significant (p= 0.122).
In order to further substantiate a differential effect of race on the associations between CYP variants and mortality among clopidogrel-treated patients following AMI, we performed a pooled association analysis and determined the interaction p-value between race and the relevant genetic variants. These analyses show a statistically significant interaction between race and mortality for CYP2C19*2 (p=0.042) and CYP2C19*17 (p=0.011). In African American TRIUMPH patients discharged on clopidogrel, the CYP2C19*17 (- homozygotes; with an overall significant genotypic effect (p= 0.013)).
Single Variant Association with
Metabolizer Phenotype Association with Mortality
We sought to determine if there was an association of CYP2C19 metabolizer status with mortality among patients stratified by race in the TRIUMPH cohort. In Caucasian TRIUMPH patients discharged on clopidogrel, 44 subjects were CYP2C19 poor metabolizers (PM), 711 subjects were extensive metabolizers (EM; normal), 280 subjects were intermediate metabolizers (IM), and 494 subjects were ultra-rapid metabolizers (UR); 123 subjects were excluded from analysis because their metabolizer status could not be assigned according to the Mega rall sign g ificant geno no no noty classification. 22 No significant difference in mortality by CYP2C19 metabolizer status was observed among Caucasians discharged on clopidogrel after AMI in TRIUMPH (log-rank p= 0.1726)
In African American TRIUMPH patients discharged on clopidogrel, there were 23 CYP2C19 PM, 152 EM, 88 IM and 126 UR; 49 subjects were excluded from analysis because their metabolizer status could not be assigned according to the Mega classification. 22 . As seen in Figure 4 , CYP2C19 metabolizer status was significantly associated with mortality in African Americans (log-rank p= 0.0371). Individuals with PM had the highest survival (100% 1-year survival), individuals with IM or EM had the next highest (97% and 94% 1-year survival, respectively), and individuals with UR had the lowest 1-year survival (88% 1-year survival).
Discussion
Our analyses of CYP variants and outcomes among clopidogrel-treated patients following AMI revealed racial differences in the mortality association of CYP2C19 genotypes. We observed significantly increased 1-year mortality among Caucasian carriers of the loss-of-function CYP2C19*2 allele, while no increased mortality was observed among African American CYP2C19*2 carriers. In contrast, significantly increased 1-year mortality was observed among African American carriers of the gain of function CYP2C19*17 allele and the CYP1A2*1C
allele, while no difference in mortality was detected among Caucasian subjects carrying either of these two variants. To our knowledge, this is the first report of significant associations between CYP polymorphisms and mortality among African Americans and of divergent associations between mortality and CYP variants according to race.
To identify potential contributors to the observed increased mortality, we investigated the association of the same CYP polymorphisms with recurrent MI, rehospitalization for cardiac incre re eas as as ased ed ed e pla la l t te tele le l l t t t re reac a tivi vi vity ty ty ty amon on ong g g pa p p p ti ti i ien ent ts ts t t t tre re re ea ated d ed ed w wit t it ith h h h cl cl lop op opid d d dog og og ogre re rel as a as c com ompa pare asian individuals carryi yi ing g g two 'wil il ild d d-ty ype p p ' ' ' CY CY CYP P2 P C1 C1 C1 C 9 9 9 9*1 *1 *1 * l l al ll le l l le l l l s. 15 34 In contrast, two other meta-analyses, one including 11 studies involving 16,360 patients and a second including 32 studies involving 42,016 patients exposed to clopidogrel concluded that CYP2C19*2 carriers had no increased risk of cardiovascular events, although a significantly increased risk of stent thrombosis after PCI was observed in those with a loss of function allele. 25, 42 It is important to note that none of the aforementioned studies or meta-analyses provided information on African Americans.
Our finding of an association between the CYP2C19*2 allele and increased rates of MI and mortality among Caucasians are consistent with previous reports of an increased hazard of ischemic events among carriers of loss of function variants for clopidogrel metabolism. Our study, however, is the first to report significantly increased 1-year mortality in clopidogrel- isoenzyme is important in detoxification of chemicals, environmental toxins and drugs, and the
CYP1A2*1C variant has been variably linked to both increased and decreased enzyme activity in
Caucasian and Asian smokers and non-smokers. 44, 45 However, neither the variant's effect on enzyme activity in African Americans, nor its effect on clopidogrel responsiveness, has been previously investigated. In view of our findings of increased bleeding events, it is intriguing to speculate that the association between CYP1A2*1C and increased mortality in African
Americans is related to increased clopidogrel responsiveness.
African American ancestry has been previously identified with an increased risk of bleeding among patients with ST elevation MI treated with reperfusion therapy. [46] [47] [48] and among patients undergoing PCI. 49 Two recent retrospective studies involving a total of over 80,000
patients from either the National Registry of MI (NRMI) 47 or from 5 clinical trials 48 reported that among patients with ST-elevation MI treated with fibrinolysis or PCI, compared with Caucasians, African Americans had an increase in both bleeding events and mortality. 47 In a Myocardial Infarction (VALIANT) trial, 50 non-white race was associated with a significantly increased risk of gastrointestinal bleeding, the most powerful of which was use of dual antiplatelet therapy, and occurrence of gastrointestinal bleeding was associated with a significantly increased risk of all-cause death. While some of these reports speculated that the observed increased bleeding risk according to race was a result of genotypic differences between
Caucasians and African Americans, 48, 51 our study provides direct evidence of a specific genotypic explanation for increased bleeding risk in African Americans treated with clopidogrel following AMI.
There may be significant clinical implications of these observations. While the clinical use of CYP genetic testing has been controversial based on current evidence of the association of CYP2C19*2 with ischemic risk, 52 the currently available studies have failed to comprehensively evaluate the potential adverse outcomes associated with CYP variants among racially diverse populations of patients treated with clopidogrel after ACS or PCI. Our results suggest select CYP variants are associated with increased mortality among clopidogrel treated patients after AMI, and that the associated CYP variant and mechanism of increased risk may vary by race. Knowing the differences in risks associated with clopidogrel treatment, and how they vary by race, may be important in individualizing therapy to specific patients. Further study is needed to better understand how knowledge of CYP genotype might improve the management of the entire spectrum of patients who may be candidates for treatment with clopidogrel.
Our study should be interpreted in the context of several potential limitations. First, we did not measure platelet reactivity in our study. However, multiple studies have confirmed increased on-treatment platelet reactivity in CYP2C19*2 allele carriers 15, 16, 20 and decreased ontreatment platelet reactivity in CYP2C19*17 allele carriers. 14 Second, we stratified patients according to their predicted metabolizer status based on the classification suggested by Mega et al, 22 however, the observation of an association between metabolizer classification and outcomes cannot prove cause and effect and cannot exclude the possible contribution of unmeasured confounders. In addition, while the majority of patients discharged on clopidogrel were documented to still be on clopidogrel on at least one follow-up time point, due to missing data we did not have precise information on how many subjects continued on clopidogrel for the full year. Third, as discussed in the Introduction and in the Methods, we performed primary and secondary analyses. As a primary analysis, our finding that the CYP2C19*17 variant was associated with significantly increased mortality among African American TRIUMPH patients discharged on clopidogrel (log rank p-value = 1e-05) is highly significant. However, as a secondary analysis, our finding that the CYP1A2*1C variant was associated with significantly increased mortality among African American TRIUMPH patients discharged on clopidogrel (log rank p-value = 0.0064) would just reach significance if corrected for multiple comparisons and should be replicated in future cohorts. Finally, our observations in African Americans have not been independently replicated in a separate cohort. However, it should be noted that, to our knowledge, few adequately powered cohorts of genotyped subjects from outcome studies ancestry in this cohort of more than 5000 genotyped patients. 40 In the report of the effect of CYP polymorphisms on response to clopidogrel from the Therapeutic Outcomes by Optimizing Platelet Inhibition by Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial, the genetic cohort of 1477 subjects included only 10 patients of African ancestry, 22 and in the meta-analysis of CYP variants among patients predominantly undergoing PCI treated with clopidogrel reported by Mega et al, 43 there were less than 5% non-whites in a cohort of more than 9000 patients. Nevertheless, despite lack of replication, we believe there is biological and clinical plausibility for our results based on the known effects of the identified variants and the associations with specific outcome hazards observed.
In its consensus report Unequal Treatment: Confronting Racial and Ethnic Disparities in
Health Care, 26 the Institute of Medicine recommended research to identify patient characteristics and treatments that vary by race so that interventions could be developed to minimize differences in care and disparities in outcomes. Utilizing the unique opportunity provided by TRIUMPH to evaluate genetic mediators of racial disparities in outcomes among MI patients treated with clopidogrel, our investigations show that cytochrome P450 polymorphisms are associated with mortality in post-MI patients receiving clopidogrel in a race-specific manner. Understanding the mechanism by which genetic variation impacts post-MI outcomes differently in white and black patients may illuminate opportunities to improve care and, ultimately, reduce differences in outcomes by race. Values are mean SD or N (%). ACE = angiotensin converting enzyme; ARB = Angiotensin II receptor blocker; BMI= body mass index; CABG = coronary artery bypass graft surgery; CHF = congestive heart failure; CVA = cerebral vascular accident; GRACE = Global Registry of Acute Coronary Events; LV = left ventricular; MI = myocardial infarction; NSTEMI = non-ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; PVD = peripheral vascular disease; STEMI = ST-segment elevation myocardial infarction; TIA = transient ischemic attack; 
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